← Leaderboards
Derin B Keskin
Dana-Farber Cancer Inst
$4,214,235
Attributed
$7,703,641
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,703,641 · 6
By mechanism
R01$7,023,832 · 4
R21$419,926 · 1
U54$259,883 · 1
Top collaborators
- Vincent Trien-Vinh Ho4 shared
- Christopher A French3 shared
- Geoffrey I Shapiro3 shared
- Catherine Ju-Ying Wu3 shared
- Hui Feng1 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Qianben Wang$7,988,225
- Himisha Beltran$8,786,271
- Megha Padi$2,623,509
- Luca Pinello$6,835,504
- Heather Anne Parsons$1,292,279
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorCellsBindingProteomicsMalignant NeoplasmsReportingT-LymphocyteValidationEpitopesResponseTrainingPeptidesAlgorithmsPeripheral Blood Mononuclear CellAffectCollaborationsPrediction AlgorithmImmunocompetentImmunologicsT Cell ResponseCell LineDesignAllelesPrincipal Investigator
Grant awards (13)
Systematic identification of minor histocompatibility antigens to address GVHD$768,238
R01 · FY2025 · HL · contact PI
Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy$703,510
R01 · FY2025 · CA · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$657,032
R01 · FY2025 · CA
Mechanisms of lmmunosuppression in MYCN-driven Neuroblastoma$635,173
R01 · FY2025 · NS
Merkel cell polyomavirus HLA class I epitopes for generating therapeutic T cell-based cancer immunotherapy$735,360
R01 · FY2024 · CA · contact PI
Systematic identification of minor histocompatibility antigens to address GVHD$723,738
R01 · FY2024 · HL · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$629,248
R01 · FY2024 · CA
Systematic identification of minor histocompatibility antigens to address GVHD$738,508
R01 · FY2023 · HL · contact PI
Genetically engineered mouse model to improve therapy of NUT carcinoma$672,468
R01 · FY2023 · CA
Systematic identification of minor histocompatibility antigens to address GVHD$760,557
R01 · FY2022 · HL · contact PI
The Computational Tumor Immunology Core (CTIC)$259,883
U54 · FY2022 · CA · contact PI
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines$187,702
R21 · FY2019 · CA · contact PI
Physical detection of HLA-C binding peptides to identify and predict immunogenic personal neoepitopes for improving cancer vaccines$232,224
R21 · FY2018 · CA · contact PI